Kinnunen Urpo, Koistinen Pirjo, Ohtonen Pasi, Koskela Markku, Syrjälä Hannu
Department of Internal Medicine, Lapland Central Hospital, Rovaniemi, Finland.
Scand J Infect Dis. 2008;40(8):642-7. doi: 10.1080/00365540801947338.
To evaluate the effect of various chemotherapy courses on the rate of bloodstream infections (BSI) during therapy-related neutropenia, all infection episodes of adult patients with acute myeloid leukaemia (AML) during 7 y were retrospectively analysed in a university hospital. Of the 182 infection episodes in 76 AML patients, 37% (n = 68) were BSI. The riskratio (RR) of BSI was highest after regimens containing high-dose cytarabine (2.4 with 95% confidence interval (CI) 1.3-4.4) and lowest after thioguanine-containing courses (RR: 0.2, 95% CI 0.2-0.5). Chemotherapy courses per se may have an influence on the rate of BSI during neutropenia.
为评估不同化疗疗程对治疗相关中性粒细胞减少期间血流感染(BSI)发生率的影响,我们对一家大学医院7年间成年急性髓系白血病(AML)患者的所有感染发作进行了回顾性分析。在76例AML患者的182次感染发作中,37%(n = 68)为BSI。接受含大剂量阿糖胞苷方案治疗后BSI的风险比(RR)最高(2.4,95%置信区间(CI)为1.3 - 4.4),而接受含硫鸟嘌呤疗程治疗后最低(RR:0.2,95% CI为0.2 - 0.5)。化疗疗程本身可能会对中性粒细胞减少期间的BSI发生率产生影响。